Home Cart Sign in  
Chemical Structure| 20831-76-9 Chemical Structure| 20831-76-9

Structure of Gentiopicroside
CAS No.: 20831-76-9

Chemical Structure| 20831-76-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Gentiopicroside is a naturally occuring iridoid with anti-inflammatory, antibacterial and liver protecting activities.

Synonyms: Gentiopicrin; NSC 606402; SC-46058

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Gentiopicroside

CAS No. :20831-76-9
Formula : C16H20O9
M.W : 356.32
SMILES Code : C=C[C@@H]1C(C2=CO[C@H]1O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=CCOC2=O
Synonyms :
Gentiopicrin; NSC 606402; SC-46058
MDL No. :MFCD00075700
InChI Key :DUAGQYUORDTXOR-GPQRQXLASA-N
Pubchem ID :88708

Safety of Gentiopicroside

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 80 μM GPS increased glucose utilization and decreased lipid synthesis in PA-treated HepG2 cells. PMC9214054
HepG2 cells 5, 20, 40, 80, 160, 320 μM 24 h Assessed the effect of GPS on HepG2 cell viability, showing no obvious toxicity at concentrations below 320 μM. PMC9214054
GES-1 cells 0, 25, 50, 100, 200, 400 µM 48 h To evaluate the effect of Gentiopicroside on the viability of GC cells, the results showed that Gentiopicroside significantly inhibited the growth of GES-1 cells within 48 h, but was the least sensitive. PMC7700081
AGS cells 0, 25, 50, 100, 200, 400 µM 48 h To evaluate the effect of Gentiopicroside on the viability of GC cells, the results showed that Gentiopicroside significantly inhibited the growth of AGS cells within 48 h. PMC7700081
BGC-823 cells 0, 25, 50, 100, 200, 400 µM 48 h To evaluate the effect of Gentiopicroside on the viability of GC cells, the results showed that Gentiopicroside significantly inhibited the growth of BGC-823 cells within 48 h. PMC7700081
MGC-803 cells 0, 25, 50, 100, 200, 400 µM 48 h To evaluate the effect of Gentiopicroside on the viability of GC cells, the results showed that Gentiopicroside significantly inhibited the growth of MGC-803 cells within 48 h. PMC7700081
HGC-27 cells 0, 25, 50, 100, 200, 400 µM 48 h To evaluate the effect of Gentiopicroside on the viability of GC cells, the results showed that Gentiopicroside significantly inhibited the growth of HGC-27 cells within 48 h, with an IC50 value of 62.03±7.63µM. PMC7700081

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57/BL6 mice High-fat diet (HFD) and streptozotocin (STZ)-induced diabetic mouse model Intragastric administration 25, 50, 100 mg/kg 6 consecutive days per week for 8 weeks GPS improved disordered glucose and lipid metabolism in STZ-HFD-induced diabetic mice by activating the PI3K/AKT signaling pathway. PMC9214054
C57BL/6 mice Acute and chronic alcoholic hepatosteatosis models Oral gavage 40 and 80 mg/kg Every 12 hours for a total of three doses Gentiopicroside ameliorated acute and chronic alcohol-induced hepatic steatosis and inflammation by activating the LKB1/AMPK signaling pathway. PMC5900996
BALB/c mice Imiquimod-induced psoriasis-like dermatitis model Topical application 50 mg/cm² Once daily for 7 days To evaluate the therapeutic effects of CHI-GEN on imiquimod-induced psoriasis-like dermatitis in mice. Results showed that CHI-GEN significantly improved the severity of skin lesions and downregulated mRNA expressions of IL-6, IL-23A, and IL-17A. PMC10348341
Sprague-Dawley rats Streptozotocin-induced diabetic rat model Oral 300 mg/kg Every three days for 12 days To evaluate the enhancing effect of Gentiopicroside PLGA nanospheres on wound healing in diabetic rats. Results showed that GPS-PLGA nanospheres significantly enhanced wound healing and stimulated collagen fiber synthesis. PMC8938172
C57BL/6 mice Morphine dependence model Intraperitoneal injection 100 mg/kg Twice daily for 8 days Gent significantly attenuated the morphine-induced CPP effect and inhibited morphine dependence by downregulating GluN2B receptor expression in the NAc. PMC6493596

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.81mL

0.56mL

0.28mL

14.03mL

2.81mL

1.40mL

28.06mL

5.61mL

2.81mL

References

 

Historical Records

Categories